Press Releases

 
Press Releases
  Date Title View
Apr 25, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2017 financial results on Tuesday, May 2, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss fir...
Mar 6, 2017
- Vertex Pharmaceuticals to Acquire Cystic Fibrosis Candidate, CTP-656, from Concert Pharmaceuticals for up to $250 Million - - CTP-543 On Track to Advance Into Phase 2a Trial - - Conference Call Scheduled Today at 8:30 a.m. EST - LEXINGTON, Mass.--(BUSINESS W...
Mar 6, 2017
- Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF - - Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments - - Concert to Host Conference Call ...
Mar 4, 2017
- Program on Track to Begin Phase 2a Trial in the First Quarter of 2017 - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the results from the Company's Phase 1 single and multiple ascending dose trial evaluating CTP-543...
Mar 2, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2016, on Monday, March 6, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a....
Jan 20, 2017
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for CTP-656, Concert's next generation CFTR potentiator being developed for the treatment of cystic fibrosis. In December 2...
Jan 17, 2017
Company to Host Conference Call and Webcast Today, January 17, 2017 at 8:30 A.M. ET LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today provided further details on the development plan in the U.S. and Europe for CTP-656, a next generation ...
Dec 21, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a U.S.-based Phase 2 clinical trial evaluating CTP-656 (deuterated ivacaftor), a next generation CFTR potentiator being developed for the treatment of cystic fibrosis. CTP-656 was created ba...
Dec 14, 2016
CTP-543 to Advance into Phase 2 in First Quarter of 2017 LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the Phase 1 single and multiple ascending dose trial evaluating CTP-543 in healthy volunteers has been completed. Concert is deve...
Nov 8, 2016
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2016. "As we approach the end of the year, our team continues to make progress ...
1
...
NextLast
= add release to Briefcase